Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer

Cancer Immunology, Immunotherapy

Volumn 63, Issue 7, 2014, Pages 721-735

  Prendergast, George C ^a,b   Smith, Courtney ^a   Thomas, Sunil ^a   Mandik Nayak, Laura ^a   Laury Kleintop, Lisa ^a   Metz, Richard ^c   Muller, Alexander J ^a,b  

^a LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c New Link Genetics Corporation   (United States)

Author keywords

Cancer associated inflammation; Immune escape; Immune surveillance; Immunoediting; Immunometabolism; Tryptophan catabolism

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; ENZYME INHIBITOR; IMMUNOMODULATING AGENT; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; INDOXIMOD; INTERLEUKIN 6; KYNURENINE; MAMMALIAN TARGET OF RAPAMYCIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NLG 8189; UNCLASSIFIED DRUG; VACCINE;

ANGIOGENESIS; AUTOPHAGY; CANCER THERAPY; HUMAN; INFLAMMATION; METASTASIS; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR IMMUNITY;

ANIMALS; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INFLAMMATION; NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR ESCAPE;

EID: 84903816506     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-014-1549-4     Document Type: Review

References (103)

1. Prendergast GC, Jaffee EM (2007) Cancer immunologists and cancer biologists: why we didn't talk then but need to now. Cancer Res 67(8):3500-3504 (Pubitemid 46762127)
2. Prendergast GC (2012) Immunological thought in the mainstream of cancer research: past divorce, recent remarriage and elective affinities of the future. Oncoimmunology 1(6):793-797. doi:10.4161/onci.20909
3. Prendergast GC, Jaffee EM (eds) (2013) Cancer immunotherapy: immune suppression and tumor growth, 2nd edn. Academic Press, New York
4. Muller AJ, Prendergast GC (2005) Marrying immunotherapy with chemotherapy: why say IDO? Cancer Res 65(18):8065-8068 (Pubitemid 41330565)
5. Muller AJ, DuHadaway JB, Sutanto-Ward E, Donover PS, Prendergast GC (2005) Inhibition of indoleamine 2,3-dioxygenase, an immunomodulatory target of the tumor suppressor gene Bin1, potentiates cancer chemotherapy. Nature Med 11:312-319 (Pubitemid 40460560)
6. Muller AJ, Scherle PA (2006) Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors. Nat Rev Cancer 6(8):613-625 (Pubitemid 44140859)
7. Hou DY, Muller AJ, Sharma MD, DuHadaway J, Banerjee T, Johnson M, Mellor AL, Prendergast GC, Munn DH (2007) Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res 67(2):792-801 (Pubitemid 46192220)
8. Prendergast GC (2008) Immune escape as a fundamental trait of cancer: focus on IDO. Oncogene 27(28):3889-3900. doi:10.1038/onc.2008.35
9. Muller AJ, DuHadaway JB, Chang MY, Ramalingam A, Sutanto-Ward E, Boulden J, Soler AP, Mandik-Nayak L, Gilmour SK, Prendergast GC (2010) Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion. Cancer Immunol Immunother 59(11):1655-1663. doi:10.1007/s00262-010-0891-4
10. Smith C, Chang MY, Parker KH, Beury DW, Duhadaway JB, Flick HE, Boulden J, Sutanto-Ward E, Soler AP, Laury-Kleintop LD, Mandik-Nayak L, Metz R, Ostrand-Rosenberg S, Prendergast GC, Muller AJ (2012) IDO Is a nodal pathogenic driver of lung cancer and metastasis development. Cancer Discov 2(8):722-735. doi:10.1158/2159-8290.CD-12-0014
11. Boyland E, Williams DC (1956) The metabolism of tryptophan. 2. The metabolism of tryptophan in patients suffering from cancer of the bladder. Biochem J 64(3):578-582
12. Yoshida R, Imanishi J, Oku T, Kishida T, Hayaishi O (1981) Induction of pulmonary indoleamine 2,3-dioxygenase by interferon. Proc Natl Acad Sci USA 78(1):129-132 (Pubitemid 11131252)
13. Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B, Brown C, Mellor AL (1998) Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281:1191-1193 (Pubitemid 28406294)
14. Mellor AL, Munn DH (1999) Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? Immunol Today 20:469-473 (Pubitemid 29476077)
15. Munn DH, Mellor AL (2007) Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 117(5):1147-1154 (Pubitemid 46718399)
16. Fallarino F, Grohmann U, Vacca C, Bianchi R, Orabona C, Spreca A, Fioretti MC, Puccetti P (2002) T cell apoptosis by tryptophan catabolism. Cell Death Differ 9:1069-1077
17. Frumento G, Rotondo R, Tonetti M, Damonte G, Benatti U, Ferrara GB (2002) Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med 196(4):459-468
18. Terness P, Bauer TM, Rose L, Dufter C, Watzlik A, Simon H, Opelz G (2002) Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J Exp Med 196(4):447-457
19. Della Chiesa M, Carlomagno S, Frumento G, Balsamo M, Cantoni C, Conte R, Moretta L, Moretta A, Vitale M (2006) The tryptophan catabolite L-kynurenine inhibits the surface expression of NKp46- and NKG2D-activating receptors and regulates NK-cell function. Blood 108(13):4118-4125. doi:10.1182/blood-2006-03- 006700 (Pubitemid 44913283)
20. Fallarino F, Grohmann U, Hwang KW, Orabona C, Vacca C, Bianchi R, Belladonna ML, Fioretti MC, Alegre ML, Puccetti P (2003) Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol 4(12):1206-1212 (Pubitemid 37547898)
21. Mellor AL, Munn DH (2008) Creating immune privilege: active local suppression that benefits friends, but protects foes. Nat Rev Immunol 8(1):74-80
22. Prendergast GC, Smith C, Thomas S, Mandik-Nayak L, Laury-Kleintop LD, Metz R, Muller AJ (2014) IDO in inflammatory programming and immune suppression in cancer. In: Gabrilovich DI, Hurwitz A (eds) Tumor-induced immune suppression. Springer, New York
23. Grohmann U, Fallarino F, Puccetti P (2003) Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol 24(5):242-248 (Pubitemid 36555962)
24. Mellor AL, Munn DH (2004) IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 4(10):762-774 (Pubitemid 39336293)
25. Fallarino F, Grohmann U, You S, McGrath BC, Cavener DR, Vacca C, Orabona C, Bianchi R, Belladonna ML, Volpi C, Santamaria P, Fioretti MC, Puccetti P (2006) The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol 176(11):6752-6761 (Pubitemid 43787857)
26. Katz JB, Muller AJ, Metz R, Prendergast GC (2008) Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol Rev 222:206-221. doi:10.1111/j.1600-065X.2008.00610.x (Pubitemid 351430372)
27. Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, Boon T, Van Den Eynde BJ (2003) Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 9(10):1269-1274 (Pubitemid 37279849)
28. Liu X, Newton RC, Friedman SM, Scherle PA (2009) Indoleamine 2,3-dioxygenase, an emerging target for anti-cancer therapy. Curr Cancer Drug Targets 9(8):938-952
29. Prendergast GC, Muller AJ, Ramalingam A, Chang MY (2009) BAR the door: cancer suppression by amphiphysin-like genes. Biochim Biophys Acta 1795(1):25-36. doi:10.1016/j.bbcan.2008.09.001
30. Ge K, DuHadaway J, Du W, Herlyn M, Rodeck U, Prendergast GC (1999) Mechanism for elimination of a tumor suppressor: aberrant splicing of a brain-specific exon causes loss of function of Bin1 in melanoma. Proc Natl Acad Sci USA 96:9689-9694 (Pubitemid 29398793)
31. Pineda-Lucena A, Ho CS, Mao DY, Sheng Y, Laister RC, Muhandiram R, Lu Y, Seet BT, Katz S, Szyperski T, Penn LZ, Arrowsmith CH (2005) A structure-based model of the c-Myc/Bin1 protein interaction shows alternative splicing of Bin1 and c-Myc phosphorylation are key binding determinants. J Mol Biol 351(1):182-194 (Pubitemid 40967064)
32. Karni R, de Stanchina E, Lowe SW, Sinha R, Mu D, Krainer AR (2007) The gene encoding the splicing factor SF2/ASF is a protooncogene. Nat Struct Mol Biol 14(3):185-193. doi:10.1038/nsmb1209 (Pubitemid 46355578)
33. Anczukow O, Rosenberg AZ, Akerman M, Das S, Zhan L, Karni R, Muthuswamy SK, Krainer AR (2012) The splicing factor SRSF1 regulates apoptosis and proliferation to promote mammary epithelial cell transformation. Nat Struct Mol Biol 19(2):220-228. doi:10.1038/nsmb.2207
34. Golan-Gerstl R, Cohen M, Shilo A, Suh S, Bakacs A, Coppola L, Karni R (2011) Splicing factor hnRNP A2/B1 regulates tumor suppressor gene splicing and is an oncogenic driver in glioblastoma. Cancer Res 71(13):4464-4472. doi:10.1158/0008-5472.CAN-10-4410
35. Barekati Z, Radpour R, Lu Q, Bitzer J, Zheng H, Toniolo P, Lenner P, Zhong XY (2012) Methylation signature of lymph node metastases in breast cancer patients. BMC Cancer 12:244. doi:10.1186/1471-2407-12-244
36. Radpour R, Barekati Z, Kohler C, Lv Q, Burki N, Diesch C, Bitzer J, Zheng H, Schmid S, Zhong XY (2011) Hypermethylation of tumor suppressor genes involved in critical regulatory pathways for developing a blood-based test in breast cancer. PLoS ONE 6(1):e16080. doi:10.1371/journal.pone.0016080
37. Radpour R, Kohler C, Haghighi MM, Fan AX, Holzgreve W, Zhong XY (2009) Methylation profiles of 22 candidate genes in breast cancer using high-throughput MALDI-TOF mass array. Oncogene 28(33):2969-2978. doi:10.1038/onc.2009.149
38. Kuznetsova EB, Kekeeva TV, Larin S, Zemlyakova V, Khomyakova AV, Babenko OV, Nemtsova MV, Zaletayev DV, Strelnikov V (2007) Methylation of the BIN1 gene promoter CpG island associated with breast and prostate cancer. J Carcinog 6:9. doi:10.1186/1477-3163-6-9
39. McKenna ES, Tamayo P, Cho YJ, Tillman EJ, Mora-Blanco EL, Sansam CG, Koellhoffer EC, Pomeroy SL, Roberts CW (2012) Epigenetic inactivation of the tumor suppressor BIN1 drives proliferation of SNF5-deficient tumors. Cell Cycle 11(10):1956-1965. doi:10.4161/cc.20280
40. Muller AJ, Sharma MD, Chandler PR, Duhadaway JB, Everhart ME, Johnson BA 3rd, Kahler DJ, Pihkala J, Soler AP, Munn DH, Prendergast GC, Mellor AL (2008) Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. Proc Natl Acad Sci USA 105(44):17073-17078. doi:10.1073/pnas.0806173105
41. Prendergast GC, Metz R, Muller AJ (2010) Towards a genetic definition of cancer-associated inflammation: role of the IDO pathway. Am J Pathol 176(5):2082-2087. doi:10.2353/ajpath.2010.091173
42. Dunn GP, Old LJ, Schreiber RD (2004) The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21(2):137-148 (Pubitemid 39094044)
43. Willimsky G, Czeh M, Loddenkemper C, Gellermann J, Schmidt K, Wust P, Stein H, Blankenstein T (2008) Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness. J Exp Med 205(7):1687-1700. doi:10.1084/jem.20072016 (Pubitemid 351962031)
44. Levina V, Su Y, Gorelik E (2012) Immunological and nonimmunological effects of indoleamine 2,3-dioxygenase on breast tumor growth and spontaneous metastasis formation. Clin Dev Immunol 2012:173029. doi:10.1155/2012/173029
45. Pertovaara M, Hasan T, Raitala A, Oja S, Yli-Kerttula U, Korpela M, Hurme M (2007) Indoleamine 2,3-dioxygenase activity is increased in patients with systemic lupus erythematosus and predicts disease activation in the sunny season. Clin Exp Immunol 150(2):274-278. doi:10.1111/j.1365-2249.2007.03480.x (Pubitemid 47609560)
46. Schroecksnadel K, Winkler C, Duftner C, Wirleitner B, Schirmer M, Fuchs D (2006) Tryptophan degradation increases with stage in patients with rheumatoid arthritis. Clin Rheumatol 25(3):334-337. doi:10.1007/s10067-005-0056-6
47. Mandik-Nayak L, Allen PM (2005) Initiation of an autoimmune response: insights from a transgenic model of rheumatoid arthritis. Immunol Res 32(1-3):5-13. doi:10.1385/IR:32:1-3:005 (Pubitemid 41153610)
48. Scott GN, DuHadaway J, Pigott E, Ridge N, Prendergast GC, Muller AJ, Mandik-Nayak L (2009) The immunoregulatory enzyme IDO paradoxically drives B cell-mediated autoimmunity. J Immunol 182(12):7509-7517. doi:10.4049/jimmunol. 0804328
49. Kita H, Shiraishi Y, Watanabe K, Suda K, Ohtsuka K, Koshiishi Y, Goya T (2011) Does postoperative serum interleukin-6 influence early recurrence after curative pulmonary resection of lung cancer? Ann Thorac Cardiovasc Surg Off J Assoc Thorac Cardiovasc Surg Asia 17(5):454-460
50. Prendergast GC, Chang MY, Mandik-Nayak L, Metz R, Muller AJ (2011) Indoleamine 2,3-dioxygenase as a modifier of pathogenic inflammation in cancer and other inflammation-associated diseases. Curr Med Chem 18(15):2257-2262. doi:10.2174/092986711795656072
51. Fallarino F, Grohmann U, Puccetti P (2012) Indoleamine 2,3-dioxygenase: from catalyst to signaling function. Eur J Immunol 42(8):1932-1937. doi:10.1002/eji.201242572
52. Grohmann U, Orabona C, Fallarino F, Vacca C, Calcinaro F, Falorni A, Candeloro P, Belladonna ML, Bianchi R, Fioretti MC, Puccetti P (2002) CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 3(11):1097-1101 (Pubitemid 35363664)
53. Fallarino F, Bianchi R, Orabona C, Vacca C, Belladonna ML, Fioretti MC, Serreze DV, Grohmann U, Puccetti P (2004) CTLA-4-Ig activates forkhead transcription factors and protects dendritic cells from oxidative stress in nonobese diabetic mice. J Exp Med 200(8):1051-1062 (Pubitemid 39431129)
54. Grohmann U, Volpi C, Fallarino F, Bozza S, Bianchi R, Vacca C, Orabona C, Belladonna ML, Ayroldi E, Nocentini G, Boon L, Bistoni F, Fioretti MC, Romani L, Riccardi C, Puccetti P (2007) Reverse signaling through GITR ligand enables dexamethasone to activate IDO in allergy. Nat Med 13(5):579-586 (Pubitemid 46828479)
55. Holmgaard RB, Zamarin D, Munn DH, Wolchok JD, Allison JP (2013) Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med 210(7):1389-1402. doi:10.1084/jem.20130066
56. Munn DH, Mellor AL (2013) Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol 34(3):137-143. doi:10.1016/j.it. 2012.10.001
57. Mellor AL, Baban B, Chandler PR, Manlapat A, Kahler DJ, Munn DH (2005) Cutting edge: CpG oligonucleotides induce splenic CD19+ dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN Type 1 signaling. J Immunol 175(9):5601-5605 (Pubitemid 41508038)
58. Orabona C, Belladonna ML, Vacca C, Bianchi R, Fallarino F, Volpi C, Gizzi S, Fioretti MC, Grohmann U, Puccetti P (2005) Cutting edge: silencing suppressor of cytokine signaling 3 expression in dendritic cells turns CD28-Ig from immune adjuvant to suppressant. J Immunol 174(11):6582-6586 (Pubitemid 40705617)
59. Puccetti P (2007) On watching the watchers: IDO and type I/II IFN. Eur J Immunol 37(4):876-879
60. Yuan W, Collado-Hidalgo A, Yufit T, Taylor M, Varga J (1998) Modulation of cellular tryptophan metabolism in human fibroblasts by transforming growth factor-beta: selective inhibition of indoleamine 2,3-dioxygenase and tryptophanyl-tRNA synthetase gene expression. J Cell Physiol 177(1):174-186 (Pubitemid 28421533)
61. Belladonna ML, Volpi C, Bianchi R, Vacca C, Orabona C, Pallotta MT, Boon L, Gizzi S, Fioretti MC, Grohmann U, Puccetti P (2008) Cutting edge: autocrine TGF-beta sustains default tolerogenesis by IDO-competent dendritic cells. J Immunol 181(8):5194-5198
62. Belladonna ML, Grohmann U, Guidetti P, Volpi C, Bianchi R, Fioretti MC, Schwarcz R, Fallarino F, Puccetti P (2006) Kynurenine pathway enzymes in dendritic cells initiate tolerogenesis in the absence of functional IDO. J Immunol 177(1):130-137 (Pubitemid 43939124)
63. Belladonna ML, Orabona C, Grohmann U, Puccetti P (2009) TGF-beta and kynurenines as the key to infectious tolerance. Trends Mol Med 15(2):41-49. doi:10.1016/j.molmed.2008.11.006
64. Pallotta MT, Orabona C, Volpi C, Vacca C, Belladonna ML, Bianchi R, Servillo G, Brunacci C, Calvitti M, Bicciato S, Mazza EM, Boon L, Grassi F, Fioretti MC, Fallarino F, Puccetti P, Grohmann U (2011) Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat Immunol 12(9):870-878. doi:10.1038/ni.2077
65. McGaha TL, Huang L, Lemos H, Metz R, Mautino M, Prendergast GC, Mellor AL (2012) Amino acid catabolism: a pivotal regulator of innate and adaptive immunity. Immunol Rev 249(1):135-157. doi:10.1111/j.1600-065X.2012.01149.x
66. Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, Trump S, Schumacher T, Jestaedt L, Schrenk D, Weller M, Jugold M, Guillemin GJ, Miller CL, Lutz C, Radlwimmer B, Lehmann I, von Deimling A, Wick W, Platten M (2011) An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 478(7368):197-203. doi:10.1038/nature10491
67. Mezrich JD, Fechner JH, Zhang X, Johnson BP, Burlingham WJ, Bradfield CA (2010) An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol 185(6):3190-3198. doi:10.4049/jimmunol. 0903670
68. Stevens EA, Mezrich JD, Bradfield CA (2009) The aryl hydrocarbon receptor: a perspective on potential roles in the immune system. Immunology 127(3):299-311. doi:10.1111/j.1365-2567.2009.03054.x
69. Metz R, Duhadaway JB, Kamasani U, Laury-Kleintop L, Muller AJ, Prendergast GC (2007) Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res 67(15):7082-7087. doi:10.1158/0008-5472.CAN-07-1872 (Pubitemid 47206533)
70. Vogel CF, Goth SR, Dong B, Pessah IN, Matsumura F (2008) Aryl hydrocarbon receptor signaling mediates expression of indoleamine 2,3-dioxygenase. Biochem Biophys Res Commun 375(3):331-335. doi:10.1016/j.bbrc.2008.07.156
71. Metz R, Smith C, Duhadaway JB, Chandler P, Baban B, Merlo LM, Pigott E, Keough MP, Rust S, Mellor AL, Mandik-Nayak L, Muller AJ, Prendergast GC (2014) IDO2 is critical for IDO1-mediated T cell regulation and exerts a non-redundant function in inflammation. Int Immunol. doi:10.1093/intimm/dxt073
72. Munn DH, Sharma MD, Baban B, Harding HP, Zhang Y, Ron D, Mellor AL (2005) GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 22(5):633-642 (Pubitemid 40719198)
73. Hu HM, Tian Q, Baer M, Spooner CJ, Williams SC, Johnson PF, Schwartz RC (2000) The C/EBP bZIP domain can mediate lipopolysaccharide induction of the proinflammatory cytokines interleukin-6 and monocyte chemoattractant protein-1. J Biol Chem 275(21):16373-16381. doi:10.1074/jbc.M910269199 (Pubitemid 30366955)
74. Metz R, Rust S, Duhadaway JB, Mautino MR, Munn DH, Vahanian NN, Link CJ, Prendergast GC (2012) IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: a novel IDO effector pathway targeted by D-1-methyl-tryptophan. Oncoimmunology 1(9):1460-1468. doi:10.4161/onci.21716
75. Cobbold SP, Adams E, Farquhar CA, Nolan KF, Howie D, Lui KO, Fairchild PJ, Mellor AL, Ron D, Waldmann H (2009) Infectious tolerance via the consumption of essential amino acids and mTOR signaling. Proc Natl Acad Sci USA 106(29):12055-12060. doi:10.1073/pnas.0903919106
76. Peter C, Waldmann H, Cobbold SP (2010) mTOR signalling and metabolic regulation of T cell differentiation. Curr Opin Immunol 22(5):655-661. doi:10.1016/j.coi.2010.08.010
77. Chuang HC, Lan JL, Chen DY, Yang CY, Chen YM, Li JP, Huang CY, Liu PE, Wang X, Tan TH (2011) The kinase GLK controls autoimmunity and NF-kappaB signaling by activating the kinase PKC-theta in T cells. Nat Immunol 12(11):1113-1118. doi:10.1038/ni.2121
78. Baban B, Chandler P, McCool D, Marshall B, Munn DH, Mellor AL (2004) Indoleamine 2,3-dioxygenase expression is restricted to fetal trophoblast giant cells during murine gestation and is maternal genome specific. J Reprod Immunol 61(2):67-77 (Pubitemid 38446980)
79. Chang MY, Smith C, Duhadaway JB, Pyle JR, Boulden J, Peralta Soler A, Muller AJ, Laury-Kleintop LD, Prendergast GC (2011) Cardiac and gastrointestinal liabilities modulatory enzyme indoleamine 2,3-dioxygenase. Cancer Biol Ther 12(12):1050-1058. doi:10.4161/cbt.12.12.18142
80. Friberg M, Jennings R, Alsarraj M, Dessureault S, Cantor A, Extermann M, Mellor AL, Munn DH, Antonia SJ (2002) Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int J Cancer 101:151-155 (Pubitemid 34970907)
81. Cheever MA (2008) Twelve immunotherapy drugs that could cure cancers. Immunol Rev 222:357-368. doi:10.1111/j.1600-065X.2008.00604.x (Pubitemid 351430366)
82. Lob S, Konigsrainer A, Zieker D, Brucher BL, Rammensee HG, Opelz G, Terness P (2009) IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism. Cancer Immunol Immunother 58(1):153-157. doi:10.1007/s00262-008-0513-6
83. Yuasa HJ, Ball HJ, Austin CJ, Hunt NH (2010) 1-l-methyltryptophan is a more effective inhibitor of vertebrate IDO2 enzymes than 1-d-methyltryptophan. Comp Biochem Physiol B Biochem Mol Biol. doi:10.1016/j.cbpb.2010.04.006
84. Qian F, Liao J, Villella J, Edwards R, Kalinski P, Lele S, Shrikant P, Odunsi K (2012) Effects of 1-methyltryptophan stereoisomers on IDO2 enzyme activity and IDO2-mediated arrest of human T cell proliferation. Cancer Immunol Immunother. doi:10.1007/s00262-012-1265-x
85. Merlo LM, Pigott E, Duhadaway JB, Grabler S, Metz R, Prendergast GC, Mandik-Nayak L (2014) IDO2 is a critical mediator of autoantibody production and inflammatory pathogenesis in a mouse model of autoimmune arthritis. J Immunol 92(5):2082-2090. doi:10.4049/jimmunol.1303012
86. Lob S, Konigsrainer A, Rammensee HG, Opelz G, Terness P (2009) Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees? Nat Rev Cancer 9(6):445-452. doi:10.1038/nrc2639
87. Prendergast GC, Metz R (2012) A perspective on new immune adjuvant principles: reprogramming inflammatory states to permit clearance of cancer cells and other age-associated cellular pathologies. Oncoimmunology 1(6):924-929. doi:10.4161/onci.21358
88. Fu T, He Q, Sharma P (2011) The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy. Cancer Res 71(16):5445-5454. doi:10.1158/0008-5472.CAN-11-1138
89. Xie DL, Wu J, Lou YL, Zhong XP (2012) Tumor suppressor TSC1 is critical for T-cell anergy. Proc Natl Acad Sci USA 109(35):14152-14157. doi:10.1073/pnas.1119744109
90. Soliman H, Antonia S, Sullivan D, Vahanian N, Link C (2009) Overcoming tumor antigen anergy in human malignancies using the novel indeolamine 2,3-dioxygenase (IDO) enzyme inhibitor, 1-methyl-D-tryptophan (1MT). J Clin Oncol 27:15s
91. Malachowski WP, Metz R, Prendergast GC, Muller AJ (2005) A new cancer immunosuppression target: indoleamine 2,3-dioxygenase (IDO). A review of the IDO mechanism, inhibition, and therapeutic applications. Drugs Fut 30:897-913
92. Sugimoto H, Oda SI, Otsuki T, Hino T, Yoshida T, Shiro Y (2006) Crystal structure of human indoleamine 2,3-dioxygenase: catalytic mechanism of O2 incorporation by a heme-containing dioxygenase. Proc Natl Acad Sci USA 103:2311-2316
93. Liu X, Shin N, Koblish HK, Yang G, Wang Q, Wang K, Leffet L, Hansbury MJ, Thomas B, Rupar M, Waeltz P, Bowman KJ, Polam P, Sparks RB, Yue EW, Li Y, Wynn R, Fridman JS, Burn TC, Combs AP, Newton RC, Scherle PA (2010) Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood 115(17):3520-3530. doi:10.1182/blood-2009-09-246124
94. Koblish HK, Hansbury MJ, Bowman KJ, Yang G, Neilan CL, Haley PJ, Burn TC, Waeltz P, Sparks RB, Yue EW, Combs AP, Scherle PA, Vaddi K, Fridman JS (2010) Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors. Mol Cancer Ther. doi:10.1158/1535-7163.MCT-09-0628
95. Sorensen RB, Berge-Hansen L, Junker N, Hansen CA, Hadrup SR, Schumacher TN, Svane IM, Becker JC, thor Straten P, Andersen MH (2009) The immune system strikes back: cellular immune responses against indoleamine 2,3-dioxygenase. PLoS ONE 4(9):e6910. doi:10.1371/journal.pone.0006910
96. Sorensen RB, Hadrup SR, Svane IM, Hjortso MC, Thor Straten P, Andersen MH (2011) Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators. Blood 117(7):2200-2210. doi:10.1182/blood-2010-06-288498
97. Sorensen RB, Kollgaard T, Andersen RS, van den Berg JH, Svane IM, Straten P, Andersen MH (2011) Spontaneous cytotoxic T-Cell reactivity against indoleamine 2,3-dioxygenase-2. Cancer Res 71(6):2038-2044. doi:10.1158/0008- 5472.CAN-10-3403
98. Iversen TZ, Engell-Noerregaard L, Ellebaek E, Andersen R, Larsen SK, Bjoern J, Zeyher C, Gouttefangeas C, Thomsen BM, Holm B, Thor Straten P, Mellemgaard A, Andersen MH, Svane IM (2014) Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase. Clin Cancer Res 20(1):221-232. doi:10.1158/1078-0432.CCR-13-1560
99. Sayama S, Yoshida R, Oku T, Imanishi J, Kishida T, Hayaishi O (1981) Inhibition of interferon-mediated induction of indoleamine 2,3-dioxygenase in mouse lung by inhibitors of prostaglandin biosynthesis. Proc Natl Acad Sci USA 78(12):7327-7330 (Pubitemid 12186133)
100. Basu GD, Tinder TL, Bradley JM, Tu T, Hattrup CL, Pockaj BA, Mukherjee P (2006) Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of IDO. J Immunol 177(4):2391-2402 (Pubitemid 44201000)
101. Lee SY, Choi HK, Lee KJ, Jung JY, Hur GY, Jung KH, Kim JH, Shin C, Shim JJ, In KH, Kang KH, Yoo SH (2009) The immune tolerance of cancer is mediated by IDO that is inhibited by COX-2 inhibitors through regulatory T cells. J Immunother 32(1):22-28. doi:10.1097/CJI.0b013e31818ac2f7
102. Muller AJ, DuHadaway JB, Jaller D, Curtis P, Metz R, Prendergast GC (2010) Immunotherapeutic suppression of indoleamine 2,3-dioxygenase and tumor growth with ethyl pyruvate. Cancer Res 70(5):1845-1853. doi:10.1158/0008-5472. CAN-09-3613
103. Balachandran VP, Cavnar MJ, Zeng S, Bamboat ZM, Ocuin LM, Obaid H, Sorenson EC, Popow R, Ariyan C, Rossi F, Besmer P, Guo T, Antonescu CR, Taguchi T, Yuan J, Wolchok JD, Allison JP, Dematteo RP (2011) Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med 17(9):1094-1100. doi:10.1038/nm.2438